Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor
- 1 August 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16691-16749
Abstract
To identify novel D3 dopamine receptor (D3R)-selective antagonist scaffolds, we conducted a high-throughput screen of a small-molecule library using a β-arrestin recruitment assay. The lead hit compound, MLS6357, displayed unprecedented D3R selectivity as well as unusual positive allosteric modulator (PAM)-antagonist activity, which may confer unique therapeutic advantages to this scaffold. Iterative medicinal chemistry was used to synthesize and characterize 137 analogues, with several demonstrating both high D3R selectivity and improved D3R potency in β-arrestin recruitment and G protein activation assays. Two of the more promising analogues with 10-fold or greater improvements in potency, 6a and 10aa, were further characterized and found to recapitulate both the allosteric PAM-antagonism and global D3R selectivity of MLS6357. 6a and 10aa also demonstrated favorable pharmacokinetics in mice suggesting that these compounds may serve as both research tools and therapeutic leads for the treatment of neuropsychiatric disorders, including substance use disorder.Keywords
Funding Information
- UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (RX03812115)
- National Institute of Neurological Disorders and Stroke (ZIA-NS002263)
- University of Kansas (U54HG005031)
- National Institute on Drug Abuse (UG3-DA050820-01A1, Z1A-DA000606)
- National Institute of Mental Health (75N95023C00021)
- North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill (2KR891703)
This publication has 56 references indexed in Scilit:
- Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disordersMedicinal Research Reviews, 2022
- The selective dopamine D3 receptor antagonist, SR 21502, reduces cue-induced reinstatement of heroin seeking and heroin conditioned place preference in ratsDrug and Alcohol Dependence, 2015
- Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesCell, 2015
- The selective dopamineD3receptor antagonistSB‐277011‐Asignificantly decreases binge‐like consumption of ethanol inC57BL/J6 miceSynapse, 2015
- Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click ChemistryAngewandte Chemie International Edition, 2014
- Dopamine D3 receptor antagonist SB-277011A inhibits methamphetamine self-administration and methamphetamine-induced reinstatement of drug-seeking in ratsEuropean Journal of Pharmacology, 2011
- The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidenceBrain Research Reviews, 2005
- Acute administration of the selective D3 receptor antagonist SB‐277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male ratsSynapse, 2003
- Antipsychotics with inverse agonist activity at the dopamine D3 receptorJournal of Neural Transmission, 1996
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973